Latest edition: 20 November 2024
Latest edition: 20 November 2024
Charity Breast Cancer Now has described the failure to negotiate a fair price of Enhertu as “utterly heartbreaking”.
The UK Health Secretary outlaid the key shifts needed to fix a “fragmented” NHS at the Jefferies London Healthcare Conference.
During the Phase III BROOKLYN trial, patients were randomly assigned in a 2:1 ratio to receive either obicetrapib 10mg or a matching placebo, orally, once daily for 52 weeks.
The FDA's feedback centres on statistical aspects concerning the proposed labelling language.
BMS's CFO David Elkins added it is “too soon to tell” what policies Trump’s new administration will bring.
Regenxbio’s plans toward a BLA filing in 2026 after positive data from the Phase I/II AFINITY DUCHENNE trial.
The agreement grants Pharmanovia exclusive rights to market the antibody for malignant ascites.
The FDA has released a draft of new guidance addressing common FAQs about the development of potential CGT treatments.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
